Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Congresswomen urge Jaguar Health to reverse price hike on drug that may be used in COVID-19 patients

Published 05/04/2020, 12:27 PM
Updated 05/04/2020, 12:30 PM
© Reuters. U.S. President Trump impeachment inquiry hearing in Washington

By Carl O'Donnell

(Reuters) - Two congresswomen wrote a letter Monday urging drugmaker Jaguar Health Inc to reverse recent price hikes on its drug Mytesi, which could be used to alleviate side effects in patients being treated for COVID-19.

The letter, signed by House Oversight Committee Chairwoman Carolyn Maloney and U.S. Representative Jackie Speier, criticized Jaguar for what it said was a nearly threefold price increase on the drug, from $688.52 to $2,206.52 per bottle of pills, earlier this month.

The letter asked the company to provide all communications pertaining to the price increases to the Committee on Oversight and Reform by May 18.

"We are concerned that the nearly three-fold price increase your company imposed ... may prevent Americans from accessing Mytesi if it is approved for use during the current coronavirus outbreak," the letter said.

Jaguar did not immediately respond to a request for comment.

San Francisco, California-based Jaguar's Mytesi is currently approved for use in addressing diarrhea and other gastrointestinal symptoms in patients being treated for HIV or AIDs with antiretroviral drugs.

In March, Jaguar applied for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration to use Mytesi to treat similar symptoms in coronavirus patients, who are also sometimes being treated with antiretroviral drugs, which reduce the severity of viral infections.

The application was denied by the FDA last month, but Jaguar Health has reportedly been in ongoing talks with the National Institute of Allergy and Infectious Diseases about the effectiveness of Mytesi for coronavirus patients, the letter said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"The timing of Jaguar’s price increase raises questions about whether this decision was connected with the company’s expectation that it eventually could market Mytesi to treat coronavirus patients," the letter said.

Gilead (NASDAQ:GILD) Science Inc's remdesivir was recently given FDA authorization to be an antiviral treatment for COVID-19, making it the first drug to be approved by U.S. regulators as a treatment for the illness, which has infected more than 1 million people in the United States and killed more than 65,000.

Remdesivir was originally developed as a treatment for the Ebola virus. Other antiviral drugs, such as hydroxychloroquine, have also been used off-label to treat patients with the coronavirus.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.